FDA, Industry Call For Human Factors Approaches To Assuring Data Integrity
This article was originally published in The Gold Sheet
Executive Summary
Human factors could be the key to data integrity. Agency and industry officials envision ways to stem the flow of data integrity warning letters and ensure data integrity by design with robust electronic production control systems and strong top-down cultural reforms.
You may also be interested in...
Manufacturing Problems Aren't Rising, But It Was A Hot July
Lack of readiness derails eye drugs from Valeant and Ocular, which now must convince FDA they know what they are making; meanwhile, an expert shares how mistake-proofing processes can help.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.